• OPEN AN ACCOUNT
Indian Indices
Sensex
73,666.57 420.54
( 0.57%)
Global Indices
Nasdaq
52,520.99 122.42
(0.23%)
Dow Jones
7,766.26 22.66
(0.29%)
Hang Seng
64,060.29 791.92
(1.25%)
Nikkei 225
10,683.77 -2.77
(-0.03%)
Forex
USD-INR
95.08 -0.03
(-0.03%)
EUR-INR
106.01 -0.48
(-0.45%)
GBP-INR
126.67 -0.36
(-0.28%)
JPY-INR
0.60 0.00
(-0.36%)

EQUITY - MARKET SCREENER

BN Agrochem Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
526125
INE00HZ01011
33.0557144
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
BNAGROCHEM
62.73
1226.56
EPS(TTM)
Face Value()
Div & Yield %
2
10
0
 

Indoco Remedies soars after Goa plant clears UK MHRA cGMP inspection
Sep 10,2026
The inspection of the facility, which manufactures solid oral dosage forms, was conducted from 7 September 2026 to 9 September 2026. The UK MHRA's current Good Manufacturing Practices (cGMP) inspection concluded with no critical or major observations, indicating compliance with the regulator's applicable manufacturing standards.

Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with a strong global presence. It develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. Top Indoco brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69, etc.

The company reported a consolidated net profit of Rs 64.99 crore in Q1 FY27 as against a net loss of Rs 35.79 crore in Q1 FY26. Revenue from operations rose 8.43% year on year to Rs 466.22 crore in the first quarter of FY27 from Rs 430.86 crore in the corresponding quarter last year.